文献速递生殖医学产科

胚胎植入前非整倍体检测对产科和新生儿结局的影响:系统综述与荟萃分析

The effect of preimplantation genetic testing for aneuploidy (PGT-A) on obstetric and neonatal outcomes: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod · 2026-01-01

该系统综述与荟萃分析比较了经滋养外胚层活检和优选全胚冷冻的PGT-A妊娠与未行PGT-A的IVF/ICSI妊娠的产科和新生儿结局。共纳入12项研究、56 113例活产,其中PGT-A组17 254例、非PGT-A组38 859例。主要分析和仅冻胚移植周期的亚组分析均未发现PGT-A与任何不良产科或新生儿结局显著相关。

要点

  • PGT-A未增加高血压疾病、早产、异常胎盘种植、低出生体重等风险。
  • 证据主要来自回顾性研究,部分结局病例数较少,需谨慎解读。
  • 当前证据不支持PGT-A对产科或新生儿有不良影响。

核心结论

  • 在均质不孕人群中,PGT-A未与任何不良产科或新生儿结局相关。

研究设计与样本

  • 系统检索PubMed、Embase和Cochrane Library,最终纳入12项随机临床试验或队列研究,共56 113例活产。

主要发现

  • PGT-A组17 254例活产,非PGT-A组38 859例活产,主要分析和仅冻胚移植周期亚组分析均无显著差异。

关键数值与推荐

  • 纳入标准包括比较IVF/ICSI联合或不联合PGT-A、囊胚培养、滋养外胚层活检和玻璃化冷冻。
  • 主要结局为高血压疾病、早产、异常胎盘种植、低出生体重、极低出生体重和小于胎龄儿。

临床怎么用

  • 咨询时可告知不孕患者当前证据未显示PGT-A增加不良产科或新生儿结局风险。

局限性

  • 纳入研究主要为回顾性,部分结局病例数较少,罕见结局需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are pregnancies after preimplantation genetic testing for aneuploidy (PGT-A) with trophectoderm (TE) biopsy and preferable elective freeze-all procedure associated with an increased risk of adverse obstetric and neonatal outcomes compared to pregnancies after IVF/ICSI without PGT-A? SUMMARY ANSWER: In this systematic review and meta-analysis specifically focusing on comparing a homogenous infertile population treated with IVF/ICSI, PGT-A was not associated with any adverse obstetric or neonatal outcomes. WHAT IS KNOWN ALREADY: An increased risk of hypertensive disorders of pregnancy (HDP) following IVF/ICSI with PGT in general as compared to IVF/ICSI without PGT has been reported. However, people undergoing PGT for monogenic diseases or structural rearrangements are often fertile in contrast to infertile people undergoing general IVF/ICSI treatment. STUDY DESIGN, SIZE DURATION: A systematic literature search was performed in PubMed, Embase, and Cochrane Library on 15 November 2024 and the search was updated on 11 June 2025. Inclusion criteria were: (i) randomized clinical trials or cohort studies comparing IVF/ICSI with or without PGT-A, (ii) embryo cultivation until the blastocyst stage, (iii) TE biopsy, and (iv) vitrification as cryopreservation method. Exclusion criteria were: (i) case series and case reports, (ii) polar body- or cleavage-stage biopsy, (iii) slow freeze, (iv) use of donor oocytes, or (v) natural conception controls. The main outcomes were HDP, preterm delivery, abnormal placentation, low birth weight, very low birth weight, and small for gestational age. PARTICIPANTS/MATERIALS, SETTING, METHODS: Meta-analyses were performed for outcomes reported in ≥3 of the included studies. Frozen embryo transfer (FET)-cycles only subgroup-analyses were performed if the data were available in ≥3 of the included studies. Newcastle-Ottawa quality assessment score and Risk-of-Bias 2 were used to assess potential bias in the individual studies, and the GRADE approach was used to assess the certainty of evidence. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 2260 records were screened, and 12 studies comprising 56 113 live births were included, of which 17 254 resulted from PGT-A and 38 859 resulted from IVF/ICSI without PGT-A. No outcomes differed significantly between the PGT-A and non-PGT-A group in the main analyses or the subgroup-analyses on FET-cycles. LIMITATIONS, REASONS FOR CAUTION: The included studies were mainly retrospective, and the number of cases was low for some outcomes. WIDER IMPLICATIONS OF THE FINDINGS: Current evidence does not suggest adverse obstetric or neonatal effects of PGT-A, though further research is needed, particularly for rare outcomes. STUDY FUNDING/COMPETING INTERTEST(S): This study was not funded. A.P. has received independent research grants and lecture fees from Abbott, IBSA, Gedeon Richter, Ferring, and Merck A/S. A.P. is part of research advisory boards for Gedeon Richter and Ferring Pharmaceuticals A/S. K.L. has received an independent research grant from Gedeon Richter and lecture fees from Ferring Pharmaceuticals. K.L. participated in a research advisory board for Ferring Pharmaceuticals A/S. N.F.W. has received a speaker's fee from Ferring Pharmaceuticals and travel support paid to institution from Gedeon Richter. The other authors had no conflict of interest to declare in relation to this work. REGISTRATION NUMBER: PROSPERO No: CRD42024599519.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Hyttel CB, Løssl K, Wang NF, et al. The effect of preimplantation genetic testing for aneuploidy (PGT-A) on obstetric and neonatal outcomes: a systematic review and meta-analysis. Hum Reprod. 2026. PMID: 41966094. doi:10.1093/humrep/deag049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。